(Q36262404)

13 August 2017

1 reference

title

Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases (English)

1 reference

13 August 2017

5

Sadayoshi Ito

1 reference

13 August 2017

Byung Ha Chung

1

1 reference

13 August 2017

Sun Woo Lim

2

1 reference

13 August 2017

Kyung Ohk Ahn

3

1 reference

13 August 2017

Akira Sugawara

4

1 reference

13 August 2017

Bum Soon Choi

6

1 reference

13 August 2017

Yong Soo Kim

7

1 reference

13 August 2017

Byung Kee Bang

8

1 reference

13 August 2017

Chul Woo Yang

9

1 reference

13 August 2017

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

10 Suppl

1 reference

13 August 2017

page(s)

S40-3

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

13 August 2017

1 reference

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)? activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Role of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in the development of hypertensive organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Chronic cyclosporine nephrotoxicity: new insights and preventive strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Peroxisome proliferator-activated receptors and cardiovascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Effects of mitogen-activated protein kinase pathway and co-activator CREP-binding protein on peroxisome proliferator-activated receptor-gamma-mediated transcription suppression of angiotensin II type 1 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00456.X

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1038/47254

10.1111/J.1440-1797.2005.00456.X

15 July 2023

Identifiers

DOI

1 reference

release_3hpax2fy4bazllqq5zeijbgq7q

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3hpax2fy4bazllqq5zeijbgq7q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference